Inventor · disambiguated record
Jonathan Stephen Mason
Also filed as: MASON JONATHAN S · MASON JONATHAN STEPHEN
17 granted patents·4 pending applications·138 citations·filing 1993–2022
93Inventor score
Files withHEPTARES THERAPEUTICS LTD14NXERA PHARMA UK LTD2RHONE POULENC RORER PHARMA2ASTRAZENECA AB1CONGREVE MILES STUART1
Top patents by PatentIndex Score
21 records- 0193US10112923B21,2,4-triazine-4-amine derivativesHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Oct 30, 2018·20 cites·3 claims
- 0290US5612353ASubstituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compoundsRHONE POULENC RORER PHARMA·Filed 1995·Granted Mar 18, 1997·59 cites·12 claims
- 0389US10166226B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jan 1, 2019·3 cites·16 claims
- 0489US9925178B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·4 cites·16 claims
- 0588US9808457B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Nov 7, 2017·6 cites·17 claims
- 0686US9688660B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jun 27, 2017·5 cites·13 claims
- 0784US9802935B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Oct 31, 2017·4 cites·9 claims
- 0882US8809525B21,2,4-triazine-4-amine derivativesCONGREVE MILES STUART·Filed 2011·Granted Aug 19, 2014·7 cites·11 claims
- 0981US10888561B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jan 12, 2021·2 cites·10 claims
- 1080US10300056B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted May 28, 2019·2 cites·19 claims
- 1179US10988455B21,2,4-triazine-4-amine derivativesHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Apr 27, 2021·1 cites·23 claims
- 1278US10259812B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 16, 2019·2 cites·11 claims
- 1378US9249130B21,2,4-triazine-4-amine derivativesHEPTARES THERAPEUTICS LTD·Filed 2014·Granted Feb 2, 2016·3 cites·16 claims
- 1474US12054472B21,2,4-triazine-4-amine derivativesNXERA PHARMA UK LTD·Filed 2021·Granted Aug 6, 2024·0 cites·3 claims
- 1572US12178813B2CGRP receptor antagonistsNXERA PHARMA UK LTD·Filed 2020·Granted Dec 31, 2024·0 cites·22 claims
- 1663US5541219A1-Alkoxy-2-(alkoxy- or cycloalkoxy-)-4-(cyclothioalkyl- or cyclothioalkenyl-) benzenes as inhibitors of cyclic AMP phosphodiesterase and tumor necrosis factorRHONE POULENC RORER LTD·Filed 1993·Granted Jul 30, 1996·15 cites·23 claims
- 1759US2024217930A1Sars-cov-2 mpro inhibitor compoundsHEPTARES THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1858US2024083845A1Sars-cov-2 mpro inhibitor compoundsHEPTARES THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1955US2016175314A11,2,4-triazine-4-amine derivativesHEPTARES THERAPEUTICS LTD·Filed 2015·Application pending·0 cites
- 2052US5958918ASubstituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N- (aminominomethyl)phenylalkyl!-azaheterocyclylamide compoundsRHONE POULENC RORER PHARMA·Filed 1997·Granted Sep 28, 1999·5 cites·57 claims
- 2148US2023271964A15-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancerASTRAZENECA AB·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jonathan Stephen Mason files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →